Michael Baghdassarian, M.D.
Clinical Accuracy Reviewer

Medical degree & licensure

• M.D. — Doctor of Medicine
• Active U.S. state medical board licensure (verifiable via FSMB DocInfo)
• Continuing medical education compliance maintained per state licensure requirements
• Specialty focus: GLP-1 receptor agonist therapy, obesity medicine, clinical pharmacology, telehealth-delivered chronic care

State medical board licensure verification

Public verification of any U.S. physician's status is available through the Federation of State Medical Boards (FSMB) DocInfo lookup:

→ fsmb.org/spex/ — DocInfo physician lookup

Patients and journalists can use the FSMB lookup to verify license status, disciplinary history, and specialty board certifications for any licensed U.S. physician.

Areas of clinical expertise

• GLP-1 receptor agonist clinical pharmacology
• Obesity medicine and chronic-weight-management protocols
• Compounded medication safety review
• Clinical guideline interpretation (AACE, AAFP, USPSTF, FDA labeling)
• Drug-drug interaction analysis
• Adverse-event reporting frameworks (FAERS)
• Patient-specific clinical-justification review under 503A/503B compounding law
• Pre-publication medical fact-check

Role & responsibilities at SemaglutideGLPOne.com

• Clinical Accuracy Reviewer — Reviews all medical content for clinical accuracy, appropriate language, and clinical claim verification before publication
• FDA-labeling reviewer — Verifies that compounded-medication content does not misstate FDA-approval status or claim equivalence to brand-name products
• Trial-data reviewer — Verifies citations to STEP, SELECT, SUSTAIN, and other GLP-1 trial data are accurate and properly contextualized
• Safety-language reviewer — Ensures contraindications, adverse events, and patient-safety guidance use appropriate clinical language
• YMYL compliance — Ensures every clinical claim on the site meets Google's Quality Rater Guidelines for YMYL health content

Conflicts of interest (full transparency)

• Compensation: Independent contracted reviewer paid by Publisher Partners LLC. Fee-for-review basis. Not employed by any reviewed provider.
• NexLife relationship: None. Dr. Baghdassarian is independent from NexLife's clinical operation (Adam Kennah, M.D. serves as NexLife's Medical Director — a separate role at a separate organization).
• Direct financial relationships with other reviewed providers: None.
• Pharmaceutical companies: No relationships with Novo Nordisk, Eli Lilly, or any GLP-1 manufacturer.
• Compounding pharmacies: No relationships with any compounding pharmacy named on this site.

Review workflow

Every medical article on SemaglutideGLPOne goes through pre-publication clinical review:

1. Author drafts content with citations
2. Clinical Accuracy Reviewer (Dr. Baghdassarian) verifies each clinical statement against the cited source — FDA labeling, peer-reviewed literature, regulatory documents
3. Senior Medical Editor (Dr. Safer) performs final pharmacology and dosing review on relevant content
4. Editor-in-Chief (Dr. Walman) gives final editorial sign-off
5. Article is published with both "Last reviewed" and "Last updated" dates

Articles & reviews by this clinician

• How Semaglutide Works (mechanism review)
• Semaglutide Dosing (0.25 mg → 2.4 mg titration)
• Semaglutide Side Effects
• Contraindications and precautions
• Drug Interactions
• STEP Trial Results
• SELECT Trial Results
• SUSTAIN Trial Results
• April 2026 FDA Action Analysis
• Compounded Semaglutide Safety Overview
• Is Compounded Semaglutide Legal?

• Every commercial claim is paired with evidence at /evidence.html
• Every medical claim is reviewed for clinical accuracy by a board-certified M.D.
• Every correction is logged publicly at /corrections.html
• Every ranking-change is documented in the monthly change log
• No provider can pay to rank higher — see /how-we-make-money.html